By Lucy Radley, Head of EU Regulatory Development, ProPharma. A rare disease is defined as a condition which affects less than one in 2000 people. Although individually they are very rare, collectively they are common with one in 17 people (around 3.5 million) in the UK being affected by a… Read More
DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More
New kids on the block, Atomic AI, recently closed a $35 million series A financing. DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. … Read More
Abbey Vangeloff is the Director of Business Development, Life Sciences, at Yahara Software. She will be chairing a session at SLAS2023. DDW’s Megan Thomas catches up with Vangeloff to learn why AI and data science are so important for the future of the sector. On SLAS2023 Abbey Vangeloff says that… Read More
DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More
Charles River Laboratories and Pioneering Medicines have entered a multi-programme agreement that gives Pioneering Medicines access to artificial intelligence (AI) model Logica. Through the agreement, Pioneering Medicines will apply Logica across a portfolio of targets with the aim of creating optimised small molecules… Read More
A new multi-year strategic partnership between M2GEN and Zephyr AI will leverage clinicogenomic data, bioinformatics, and artificial intelligence to accelerate drug discovery and expanded use cases for oncology treatments. In this partnership, M2GEN will license its real-world data set (RWD) to Zephyr AI, while Zephyr AI will… Read More
DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More
At IBM Research, a group of scientists and researchers from around the globe is working to support the power of the scientific method to invent what’s next for IBM, its clients, and the world. Joshua Smith, PhD, IBM TJ Watson Research Center, speaks with DDW’s Megan Thomas about AI, and… Read More
AI company Absci and St John’s Cancer Institute (SJCI) have entered a partnership to uncover breakthrough cancer therapies. The companies will use Absci’s Integrated Drug Creation platform, which combines generative AI models and proprietary wet-lab technologies, and SJCI’s cancer biospecimen repository and molecular database to identify new… Read More
Envision Pharma Group has acquired OKRA.ai, a provider of artificial intelligence (AI) services for the pharmaceutical and life sciences industry. “We are delighted to welcome OKRA.ai into the Envision family,” said Meg Heim, CEO, Envision Pharma Group. “The combination of Envision’s leading technology, capabilities, and solutions with OKRA.ai’s artificial intelligence… Read More
Listen to this article on the DDW Podcast: Andrew A Radin Chief Executive Officer of Aria Pharmaceuticals, on the critical use of artificial intelligence in solving some of drug discovery’s most new and complex challenges. Basic research and new technologies are uncovering insights every day that build on our understanding of human… Read More
DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More
It’s impossible to be online and not hear about ChatGPT, the controversial chatbot launched by OpenAI in November 2022. Here, DDW’s Diana Spencer takes a look at the ways ChatGPT and technology like it could change the future of drug discovery and development. Chat Generative Pre-Trained Transformer (or ChatGPT) is… Read More
DDW is hosting an exclusive free event, Connected chemistry: How to choose the most promising drug candidates from your hit list. It will be supported by Torx Software. It will take place on March 8, 2023 3PM GMT. Register here for free. AI and machine learning (AI/ML)… Read More
AI and machine learning (AI/ML) methods offer an alluring way to expedite the drug discovery process by delivering a large number of possible new candidates for any given therapeutic area. However, insight from medicinal chemists is still necessary to triage and prioritise the most promising molecules for synthesis, and progress… Read More
